BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38726264)

  • 1. Identification of new microtubule small-molecule inhibitors and microtubule-associated genes against triple negative breast cancer.
    Chen J; Lin Z; Fan J; Monzavi-Karbassi B; Kelly T; Post SR; Dai L; Qin Z
    Am J Cancer Res; 2024; 14(4):1545-1560. PubMed ID: 38726264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MCAK Inhibitors Induce Aneuploidy in Triple Negative Breast Cancer Models.
    Smith JC; Husted S; Pilrose J; Ems-McClung SC; Stout JR; Carpenter RL; Walczak CE
    bioRxiv; 2023 Jun; ():. PubMed ID: 37397990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
    Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
    Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
    [No Abstract]   [Full Text] [Related]  

  • 4. A modified natural small molecule inhibits triple-negative breast cancer growth by interacting with Tubb3.
    Han H; Yang M; Wen Z; Wang X; Lai X; Zhang Y; Fang R; Yin T; Yang X; Wang X; Zhao Q; Qi J; Chen H; Lin H; Yang Y
    Phytomedicine; 2024 Apr; 126():154894. PubMed ID: 38377719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer.
    Liao L; Zhang YL; Deng L; Chen C; Ma XY; Andriani L; Yang SY; Hu SY; Zhang FL; Shao ZM; Li DQ
    Cancer Res; 2023 Feb; 83(3):471-484. PubMed ID: 36484700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
    Haynes BM; Cunningham K; Shekhar MPV
    BMC Cancer; 2022 Oct; 22(1):1073. PubMed ID: 36258187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptome Profile Analysis of Triple-Negative Breast Cancer Cells in Response to a Novel Cytostatic Tetrahydroisoquinoline Compared to Paclitaxel.
    Gangapuram M; Mazzio EA; Redda KK; Soliman KFA
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer Cells.
    Jurj A; Pop LA; Zanoaga O; Ciocan-Cârtiţă CA; Cojocneanu R; Moldovan C; Raduly L; Pop-Bica C; Trif M; Irimie A; Berindan-Neagoe I; Braicu C
    Cell Physiol Biochem; 2020 Jul; 54(4):648-664. PubMed ID: 32619350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research and experimental verification on the mechanisms of cellular senescence in triple-negative breast cancer.
    Cao T; Huang M; Huang X; Tang T
    PeerJ; 2024; 12():e16935. PubMed ID: 38435998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
    Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel biomarkers identified in triple-negative breast cancer through RNA-sequencing.
    Chen YL; Wang K; Xie F; Zhuo ZL; Liu C; Yang Y; Wang S; Zhao XT
    Clin Chim Acta; 2022 Jun; 531():302-308. PubMed ID: 35504321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line.
    Dewi C; Fristiohady A; Amalia R; Khairul Ikram NK; Ibrahim S; Muchtaridi M
    Molecules; 2022 Jun; 27(12):. PubMed ID: 35744786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenomic Profiling Advises Therapeutic Potential of Leukotriene Receptor Inhibitors for a Subset of Triple-Negative Breast Tumors.
    Kalinkin AI; Sigin VO; Kuznetsova EB; Ignatova EO; Vinogradov II; Vinogradov MI; Vinogradov IY; Zaletaev DV; Nemtsova MV; Kutsev SI; Tanas AS; Strelnikov VV
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
    Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
    Front Oncol; 2022; 12():919072. PubMed ID: 35795050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
    Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
    Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
    Thies KA; Cole MW; Schafer RE; Spehar JM; Richardson DS; Steck SA; Das M; Lian AW; Ray A; Shakya R; Knoblaugh SE; Timmers CD; Ostrowski MC; Chakravarti A; Sizemore GM; Sizemore ST
    Breast Cancer Res; 2021 Jun; 23(1):65. PubMed ID: 34118960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microtubule Acetylation-Specific Inhibitors Induce Cell Death and Mitotic Arrest via JNK/AP-1 Activation in Triple-Negative Breast Cancer Cells.
    Ahn S; Kwon A; Oh Y; Rhee S; Song WK
    Mol Cells; 2023 Jun; 46(6):387-398. PubMed ID: 36794420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
    Mehlich D; Marusiak AA
    Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer.
    Sheng J; Xue X; Jiang K
    Curr Mol Med; 2019; 19(2):147-155. PubMed ID: 30854965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
    McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
    Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.